ASND:NSD-Ascendis Pharma A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 151.94

Change

-2.09 (-1.36)%

Market Cap

USD 8.19B

Volume

0.21M

Average Target Price

USD 174.08 (+14.57%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

USD18.93B 47.64 35.20

ETFs Containing ASND

Symbol Name Weight Mer Price(Change) Market Cap
MEU:CA Mackenzie Maximum Diversi.. 0.00 % 0.61 %

+0.38 (+1.71%)

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.22% 61% D- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.22% 61% D- 70% C-
Trailing 12 Months  
Capital Gain 57.75% 70% C- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.75% 70% C- 83% B
Trailing 5 Years  
Capital Gain 758.42% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 758.42% 96% A 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 72.37% N/A N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.37% N/A N/A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 44.41% N/A N/A 27% F
Risk Adjusted Return 162.96% N/A N/A 99% A+
Market Capitalization 8.19B 96% A 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 91% A- 99% A+
Price/Book Ratio 14.20 10% F 8% F
Price / Cash Flow Ratio -46.55 92% A- 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -45.78% 67% D+ 25% F
Return on Invested Capital -51.64% 60% D- 18% F
Return on Assets -25.89% 53% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 12.51 15% F 8% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.87 77% C+ 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector